The Food and Drug Administration (FDA) has approved ProVate (ConTIPI) for the temporary, nonsurgical management of pelvic organ prolapse in women.

The ProVate device is a vaginal ring pessary with a disposable applicator. According to the Company, once the device is inserted “the ProVate support distends lateral vaginal walls aside, mechanically prevents cervical/vault descent, and with its central piece – blocks further descent of the anterior/posterior walls within the hollow of the ring.” The device is available in 6 sizes.

Healthcare professionals will need to fit patients with an appropriately sized device and provide training, however once they have been provided with instructions, patients will then be able to self-insert the ProVate device at home. Removal of the device is done by pulling a string, similar to a tampon; one device may be used for up to 7 days.

Related Articles

Commenting on the FDA approval of ProVate, Dr Elan Ziv, founder and CEO of ConTIPI said, “This is an innovative groundbreaking product, enabling women to control their medical problem and we assume that the product will soon be available to millions of women worldwide who would be interested in treatment.”

For more information visit contipi.com.

This article originally appeared on MPR